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BACKGROUND: Chemotherapy-induced febrile neutropenia is a medical emergency complicating the treatment of many cancer
patients. It is associated with considerable morbidity and mortality, as well as impacting on healthcare resources.
METHODS: A prospective study of all cases of chemotherapy-induced febrile neutropenia in the South West London Cancer Network
was conducted over a 4-month period. Factors including demographics, treatment history, management of febrile neutropenia and
outcome were recorded.
RESULTS AND CONCLUSION: Our results reflect those of the recent National Chemotherapy Advisory Group (NCEPOD, 2008)/
National Confidential Enquiry into Patient Outcomes and Death reports (NCAG, 2009) and highlight the need for network-wide
clinical care pathways to improve outcomes in this area.
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Chemotherapy-induced febrile neutropenia is associated with
substantial morbidity, mortality, and healthcare costs (Lyman
et al, 1998; Crawford et al, 2004; Kuderer et al, 2006), and is a
medical emergency prompting immediate hospitalisation in most
cases for assessment and treatment. Management of the underlying
cancer may be compromised, as delays and/or dose reductions of
subsequent courses of chemotherapy can negatively affect long-
term outcomes (Pettengell et al, 1992; Lyman, 2005; Chirivella et al,
2006; Clamp et al, 2008). The risk of febrile neutropenia and its
complications published in clinical trials may be underestimated
(Dale et al, 2003) and not reflect everyday clinical practice.
Reasons for this include selection bias and inconsistent reporting
of toxicity data. It is also important to recognise that trial data may
not reflect the widespread implications, costs and resource strain
involved in the management of neutropenic sepsis.
The costs of emergency care, inpatient and intensive care
provision, as well as increased demands on nursing and physician
time, are all consequences of neutropenic sepsis. Prevention is not
always possible, but can be achieved by primary prophylactic use
of antibiotics and haematopoietic growth factors (e.g., G-CSF),
which have been shown to decrease the incidence and mortality of
febrile neutropenia. In a systematic review of 15 randomised
controlled trials, use of prophylactic G-CSF led to a 46% decrease
in the occurrence of febrile neutropenia (Kuderer et al, 2007), and
a meta-analysis of randomised controlled trials showed that
prophylactic antibiotics resulted in fewer febrile episodes and
bacterial infections with a 34% (95% CI: 25–41%) reduction in
death(Gafter-Gvili et al, 2005).
Underpinning the issues which face the management of febrile
neutropenia, is the fact that chemotherapy services must be
provided in a safe environment that simultaneously strives for
quality. This was highlighted in the 2008 National Confidential
Enquiry into Patient Outcomes and Death (NCEPOD) report,
which provided a critical review of the care of cancer patients who
died within 30 days of receiving chemotherapy in the United
Kingdom (NCEPOD, 2008). In all, 83 admissions because of
neutropenic sepsis were recorded and significant deficiencies in
the level of care identified. Three cases were considered to have
received suboptimal care and their deaths directly attributable to
chemotherapy-related complications, with delay in treatment of
the toxicity contributing to two of the three deaths. Problem areas
identified were related to organisational, clinical and patient
aspects, and are detailed in Table 1. Delays in admission,
prescription and administration of antibiotics, lack of policies
and inadequate seniority of medical staff, were deemed to be
fundamental areas of weakness requiring urgent improvement.
The National Chemotherapy Advisory Group (NCAG) is a body
established in the United Kingdom whose role is to advise the
National Cancer Director and Department of Health on the
development and delivery of high quality chemotherapy services.
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sFollowing the concerns raised by NCEPOD, NCAG published a
set of recommendations (NCAG, 2009), encouraging service
providers to reflect on current practice and implement a step-
wise progression towards safer and better cancer care. Specific
recommendations relating to management of chemotherapy-
related complications were:
  Improved patient information about what they should do in the
event of developing a complication
  Provision of an urgent assessment facility with appropriately
trained staff
  Network coordination to ensure standardised policies and
pathways are in place and are accessible, and to develop close
links with A and E departments in neighbouring hospitals
  A 24-h telephone advice from an oncology consultant
  ‘Treat and transfer’ arrangements to be in place if facilities
do not have appropriate expertise for inpatient management
  ‘Door to delivery’ time of antibiotic administration for
neutropenic sepsis to be within 1h
  Patients’ treating oncology team to be notified of complications
within 24h
  NICE to develop a national clinical guideline on management
and prevention of neutropenic sepsis
To determine our current practice and outcomes and as an aid
towards mapping health resource implications, we conducted a
prospective study of all admissions with chemotherapy-induced
febrile neutropenia in hospitals within the South West London
Cancer Network (SWLCN). This is a single cancer network in
South East England covering a population of B1.4 million people.
We analysed our results with particular attention to the findings of
the NCEPOD data and recommendations from the NCAG report.
MATERIALS AND METHODS
Prospective patient data was captured at the seven hospitals of the
South West London Cancer Network (Epsom and St Helier
University Hospitals, Kingston Hospital, Mayday Hospital, The
Royal Marsden Hospital – Fulham Road and Sutton sites and St
George’s Hospital). All participating hospitals had pre-existing
policies for the assessment and management of neutropenic sepsis;
however these did not consistently ensure that all patients were
managed according to agreed standards, and the policies were not
standardised across the network. Over a period of 4 months
between May and August 2007, all new hospital admissions of
adult patients (aged X18) undergoing systemic therapy for a
diagnosis of malignancy and presenting with febrile neutropenia,
were documented on a shared database. Cases were identified and
screened for inclusion on a daily basis by a nominated physician at
each hospital site. Owing to concerns about capturing all patients
admitted within the network, there was agreement with the
haematology department at each hospital to screen all patients
with neutropenia and cross-reference them with admission. Febrile
neutropenia was defined as a measured body temperature of
Z381C and neutrophils o1 10
9l
 1 at first assessment.
Data for demographics, clinicopathological details, previous and
current systemic therapy, inpatient management including use of
haematopoietic growth factors and clinical outcome was recorded.
Data accrual was performed using a unified data collection tool,
which consisted of a form with pre-specified fields. Data field
groupings included: (1) patient demographics, (2) clinical details,
(3) treatment history and (4) outcome data. In total, 58 items
were obtained for each case. On completion of the study period, all
prospectively completed forms were centrally collated and data
transcribed to a centrally held, electronically secure database. The




In all, 71 admissions for febrile neutropenia were reported
involving 64 patients. In all, 7 patients were admitted on two
separate occasions, whereas the remaining 57 were admitted on a
single occasion. In all, 38 patients (59%) were female and 26 (41%)
were male. The median age was 60 years (range: 20–78 years). In
all, 50 (70%) cases were assessed and admitted to one of the two
‘cancer centres’ (St George’s Hospital and The Royal Marsden
Hospitals) within the cancer network.
Clinical details
The sites of underlying malignancies are summarised in Table 2.
The most common tumour types were breast cancer (18%) and
lymphoma (18%). Only 11 (15%) patients admitted with febrile
neutropenia were asymptomatic. All other patients had one or
more symptoms as detailed in Table 3. Most commonly,
patients complained of respiratory (49%) and gastrointestinal
(46%) symptoms. Notably, six (8%) patients presented with severe
haemodynamic compromise with a recorded systolic blood
pressure of o80mmHg. The mean presenting neutrophil count
at admission was 0.3 10
9l
 1. Information on HDU/ICU admis-
sion was not available at the time of data analysis.
Treatment history
Systemic anti-cancer therapy had been given with palliative intent
in 37 (54%) patients, with curative intent (as primary single-
modality treatment) in 17 (24%), as adjuvant (post-operative)
treatment in 9 (13%) and as neoadjuvant (pre-operative) therapy
in 6 (9%) patients. All patients had received conventional cytotoxic
chemotherapy. There were no cases due to the sole use of ‘targeted’
treatments, such as monoclonal antibodies or tyrosine kinase
inhibitors. The commonest chemotherapy regimens recorded were
cyclophosphamide, vincristine, doxorubicin and prednisolone:
eight cases (11%), docetaxel: six cases (8%), doxorubicin and
cyclophosphamide: five cases (7%), infusional 5-fluorouracil with
irinotecan: four cases (6%), and 5-fluorouracil, epirubicin,
cyclophosphamide: 3 cases (4%). In all, 44% patients had received
anthracyclines as part of their chemotherapy. Febrile neutropenia
occurred at a median of 10 days (range: 5–21) after starting the
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slast course of chemotherapy and 36 (50%) episodes occurred after
cycles 1 or 2. In all, 11 (15%) patients had an indwelling central
venous catheter present. In all, 19 (25%) patients had received
antibiotics as primary prophylaxis and 17 (23%) patients had
received primary prophylactic G-CSF. Amongst the group that
received prophylactic G-CSF, the most common diagnoses were
lymphoma (six patients) and sarcoma (four patients).
Almost all (98%) patients in our data series had (level I/II
evidence for patient related) risk factors for the development of
febrile neutropenia, as described by the American Society of
Clinical Oncology (ASCO) and European Organisation of Research
and Treatment of Cancer (EORTC) guidelines (Table 4). In all, 39
(54%) patients had advanced stage disease, 25 (35%) patients were
X65 years old and 18 (25%) had had a previous neutropenic event.
In all, 23 (32%) patients had received systemic therapy with at least
20% risk of febrile neutropenia.
Outcome data
A total of 45 (63%) patients were admitted directly to a specialist
oncology or haematology ward. In all, 21 (30%) were seen in the
accident and emergency department first. The median time from
arrival to nursing assessment and recording of observations
was 10min (range: 0–135). The median time to first assessment
by a clinician was 40min (range: 0–230). Data on the seniority of
admitting clinician was not specifically recorded, however, based
on medical rotas within the SWLCN, was likely to be FY1/2 (post-
completion medical degree year 1–2) and ST1/2 (post-completion
medical degree year 2–4) doctors. The median time from arrival
to administration of an antibiotic was 135min (range: 15–550)
9 out of 50 patients received antibiotics within 60min (‘time of
antibiotics’ data only available for 50 patients). Regarding clinical
investigations: chest x-ray was obtained in 62 (87%) patients,
urinalysis by dip-stick testing in 55 (71%) cases; blood cultures
were obtained in 66 (92%), urine cultures in 52 (73%) and stool
cultures in 27 cases (38%).
All patients received intravenous antibiotics. At the time of data
analysis, information on whether first-line antibiotics were
appropriate and compliant with local policies was not available.
In all, 22 (30%) patients required ‘second-line’ treatment, whereby
antibiotics were changed after 48h of persisting intermittent fever
of 38
oC or above. In all, 12 (17%) patients received additional
antifungal regimens. In all, 45 (63%) patients received treatment
with G-CSF. The median duration of hospital stay was 5 days
(range: 2–60). Patients with no symptoms (11 cases, 15%) had the
shortest stay (median of 4 days) compared with patients
presenting with three or more symptoms (9 cases, 13%), who
remained in hospital longer (median of 22 days).
Admission for febrile neutropenia resulted in delay of sub-
sequent administration of chemotherapy in 19 (26%) patients,
complete cessation of chemotherapy in 5 (7%) patients and dose
reduction in 10 (14%) patients. Of these, one was receiving
adjuvant therapy and had already received primary prophylactic
G-CSF. The remaining nine patients were being treated with
palliative intent. The median age of all patients who had dose
reductions was 68 years (range: 32–75).
In all, 4 (6%) patients died during their admission to hospital
for febrile neutropenia. A 67 year-old lady with natural killer cell
lymphoma died 25 days after admission. Her death was not
attributed to febrile neutropenia but rather to co-morbidities,
including congestive cardiac failure, pneumothorax and ultimately
a perforated abdominal viscus. However, in the other three cases,
neutropenic sepsis was deemed to be the main cause of death.
These patients were: (1) a 59 year old with relapsed lymphoma
admitted after his sixth cycle of palliative chemotherapy who died
on the day after admission; (2) a 61 year old with acute
myelogenous leukaemia receiving palliative chemotherapy who
died 9 days after admission; and lastly, (3) a 59 year old patient
with small cell lung cancer receiving second-line chemotherapy
who died on the day of admission. In this last case, sepsis-related
death occurred 12 days following commencement of cycle 1 of
palliative second-line chemotherapy.
DISCUSSION
The NCAG recommendations set a benchmark for maintaining
existing cancer services and for development and improvement
where required. Neutropenic sepsis is one of the key areas
highlighted and cancer networks must work to provide an acute
oncology service with standardised protocols and policies,
ensuring that patients receive antibiotics within one hour of
presentation (door-to-needle; NCAG, 2009). Our study demon-
strates that within SWLCN, chemotherapy-induced febrile neutro-
penia was generally recognised early and managed appropriately,
however there remains room for improvement. Timely adminis-
tration of appropriate antibiotics within 60min requires particular
attention. The seriousness of the condition is underlined by the
fact that three patients died as a direct consequence of neutropenic
sepsis, translating into a mortality rate of 4.2% for our series. This
is in keeping with reported mortality rates of between 2 and 10%
(Kuderer et al, 2006; Klastersky and Paesmans, 2007).
Table 2 Primary sites of underlying malignancies of cancer patients
presenting with febrile neutropenia
Underlying malignancy Number of cases, n¼71 (%)
Breast cancer 13 (18)
Lymphoma 13 (18)
Other haematological malignancy 11 (15)
Sarcoma 9 (12)
Lung cancer 8 (11)
Lower gastrointestinal cancer 7 (10)
Other 6 (8)
Upper gastrointestinal cancer 4 (6)
Table 3 Presenting symptoms on admission







Table 4 Prevalence of (level I/II evidence for) risk factors for the
development of febrile neutropenia (according to ASCO and EORTC
guidelines)
Risk factor (level I/II evidence)
Number of cases,
n¼71 (%)
Advanced disease 39 (54)
Age X65 years 25 (35)
Previous neutropenic event 18 (25)
No prophylactic treatment (G-CSF and/or antibiotic
treatment)
43 (60)
Chemotherapy Z20% risk for febrile neutropenia 23 (32)
Abbreviations: ASCO¼American Society of Clinical Oncology; EORTC¼European
Organisation of Research and Treatment of Cancer; G-CSF¼granulocyte colony-
stimulating factor.
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sThe NCEPOD report (NCEPOD, 2008) revealed similar pro-
blems in delayed administration of antibiotics, the use of incorrect
antibiotics and delay in both diagnosis and senior staff review.
Recommendations include access to a local policy and clinical care
pathway, management by experienced staff, as well as close liaison
with A and E departments. It was apparent in our study that there
was no common protocol that existed between the hospitals of the
network, and this may have contributed towards delayed manage-
ment and use of antibiotics, but also accounts for the variation
of diagnostics undertaken. The National Comprehensive Cancer
Network (NCCN) guidelines (Aapro et al, 2006; Smith et al, 2006)
recommend routine blood tests and blood cultures for all patients,
but other investigations such as chest x-rays, dip-stick urinalysis,
urine and stool cultures, are left at the discretion of the assessing
clinician. As time is a highly significant factor in the successful
management of neutropenic sepsis, a network-based protocol
would aid in expediting assessment and early treatment.
Almost all patients included in our study had well-established
risk factors for the development of febrile neutropenia. American
and European guidelines (Aapro et al, 2006; Smith et al, 2006)
acknowledge the following factors as significant for considera-
tion of prophylactic administration of haematopoietic growth
factors: (1) chemotherapy regimens with a risk of 420% for the
development of febrile neutropenia or (2) regimens with a risk
between 10 and 20% in conjunction with certain patient-related
risk factors such as stage of disease and age. Of our patients that
fulfilled either of these criteria, only 21% and 43%, respectively,
received G-CSF (Table 5). Primary prophylactic G-CSF can reduce
the risk of febrile neutropenia by 46% and infection-related
mortality by 45%, whilst also allowing improved relative dose
intensity of chemotherapy (Kuderer et al, 2007). In all, 50% of all
episodes of febrile neutropenia occurred at or near the start of a
chemotherapy course (cycles 1 and 2). This is in keeping with
previous reports (Lyman, 2005), which led to the recommendation
for starting prophylactic measures ‘upfront’ in appropriate risk
groups (Aapro et al, 2006; Smith et al, 2006; NCCN, 2009).
Identification of patients who will benefit from G-CSF and
improving access to these agents is an important process before
the commencement of chemotherapy.
Of note, one-third of patients with febrile neutropenia in our
study were older than 65 years, and this may support the notion
that increasing age is an independent predictor of the development
of febrile neutropenia (Crawford et al, 2004; Aapro et al, 2006).
There is sufficient evidence that prophylactic G-CSF reduces the
incidence of chemotherapy-induced neutropenia, febrile neutro-
penia and infections in elderly patients (Repetto et al, 2003).
Increased use of growth factors may be particularly relevant in the
elderly, in order to optimise their cancer care and quality of life.
Older patients are frequently under-treated because of mispercep-
tions of their frailty; however dose reductions may compromise
treatment efficacy (Pietropaolo et al, 2003; Lyman et al, 2004).
Growth factors may help these management dilemmas.
Use of G-CSF in treatment of febrile neutropenia is more
controversial and although 63% of our patients received G-CSF as
secondary treatment, this may not necessarily be representative of
other networks. The ASCO and EORTC guidelines recommend
colony-stimulating factors as treatment only for patients who are
at high risk for infection-associated complications. A meta-
analysis (Clark et al, 2005) showed a significant reduction in the
length of hospitalisation (hazard ratio: 0.63, 95% CI: 0.49–0.82,
P¼0.0006) with the use of G-CSF, but only a marginally signifi-
cant decrease in infection-related mortality (odds ratio: 0.51,
95% CI: 0.26–1.00, P¼0.05) and no significant reduction in
overall mortality.
Primary antibiotic prophylaxis was used in 25% of cases in our
study and its efficacy in reducing infections, febrile neutropenia
and hospital admissions has been shown (Engels et al, 1998; Cullen
et al, 2005). However there are valid concerns pertaining to
possible increases in antimicrobial-resistant strains (Goossens
et al, 2005), and widespread use is therefore discouraged for
standard chemotherapy regimens in most solid tumours. Use may
be considered for intermediate risk groups, such as lymphoma
patients and treatments in which prolonged (7–10 days)
neutropenia is anticipated (Cullen et al, 2007; NCCN, 2008).
It is important to recognise that prevention of neutropenic
sepsis and its complications begins with appropriate, considered
commencement of chemotherapy. Of particular concern from the
NCEPOD was the finding that in 19% of cases, the decision to give
chemotherapy was inappropriate, mostly on the grounds of
progressive disease and abnormal blood results. Furthermore, in
27% of cases, chemotherapy was judged to have hastened or
Table 5 Risk stratification according to ASCO/EORTC guidelines and









Advanced disease 39 5 (13)
Regimen with 10–20% risk
of febrile neutropenia and
age Z65
14 3 (21)




Regimen 420% risk for febrile
neutropenia
23 10 (43)
Abbreviations: ASCO¼American Society of Clinical Oncology; EORTC¼European
Organisation of Research and Treatment of Cancer; G-CSF¼granulocyte colony-
stimulating factor.
Table 6 Key areas for improvement and action points for SWLCN
Key areas for improvement
Improve time to antibiotics
Develop a structured education and monitoring process for high risk patients
Improve uptake of prophylactic antibiotics for high risk patients
Key actions
New clinical pathway – streamlined to avoid delays
Within 10min of
presentation
Assessment and observations, blood tests and
antibiotics sourced, senior designated person contacted
Within 1h of
presentation
Administration of intravenous antibiotic
Medical assessment




Ongoing monitoring and review
Within 4h of
presentation
Patients requiring inpatient stay are admitted
to hospital
Development of acute oncology service within each cancer centre
Development of standardised SWLCN protocol for management of
neutropenic sepsis
Patient information
Reviewed and developed in partnership with patients; for example, the
patient alert card to help patients understand when and how to access
emergency help and advice
Education and training package for staff
Implementation of the HEAT (history, examine, action and treat tool; Dikken,
2009). This consists of a poster, patient alert card and DVD outlining
symptoms of neutropenic sepsis and required actions
Ongoing audit
Abbreviations: DVD¼digital video disc; SWLCN¼South West London Cancer Network.
A study of chemotherapy-induced febrile neutropenia
M Okera et al
410















scaused death, with the peak of deaths occurring 11–15 days after
chemotherapy and likely related to the development of neutro-
penic sepsis (NCEPOD, 2008). For our data series, there was one
case (1.4%) of death within 30 days of commencing chemotherapy,
and with hindsight perhaps the use of second-line chemotherapy
in this patient with metastatic SCLC was inappropriate. The NCAG
recommendations provide a framework for a process of assess-
ment, decision to treat, informed consent and prescription of
chemotherapy, and emphasise the importance of detailed standar-
dised consent forms and the involvement of senior trained
oncology medical staff (NCAG, 2009). The evaluation of these
aspects was beyond the scope of this study but will be an area of
focus within the network.
Our study was also limited in being able to capture patients
receiving chemotherapy at SWLCN hospitals but who presented
with febrile neutropenia at hospitals outside the network. The
NCEPOD reported that 15% of admissions were to hospitals other
than the one where chemotherapy had been administered
(NCEPOD, 2008). Peripheral hospitals may not be equipped with
24-h oncology services and similar levels of experience and it is
therefore even more crucial for these sites to have access to well-
designed protocols and to expert consultant advice. As outlined by
NCAG, patient education regarding what to do in the event of a
chemotherapy-induced complication is fundamental to ensuring
they receive prompt appropriate care. Evaluating the efficacy of
current patient education processes was also beyond the scope
of this study, and in particular, it will be useful to assess the use of
pre-designed ‘neutropenic sepsis’ cards which patients present to
their local A and E in order to expedite appropriate management.
All patients in our study were treated with intravenous
antibiotics and were admitted for inpatient care. Recent advances
in the management of febrile neutropenia have highlighted the
value of risk stratification and the evolving role of oral antibiotics
with early hospital discharge in low-risk patients (Freifeld et al,
1999; Kern et al, 1999; Hughes et al, 2002). The Multinational
Association for Supportive Care in Cancer has developed a risk
index for the development of febrile neutropenia (Klastersky and
Paesmans, 2007) and studies have shown that outpatient oral
antibiotics are feasible in low-risk patients (Innes et al, 2003; Vidal
et al, 2004; Klastersky and Paesmans, 2007). To our knowledge,
this stratification is not routinely used in the UK (Innes et al, 2005)
but will be an increasing area of interest, with important
implications on decreased inpatient costs and improved patient
convenience with outpatient care.
Undoubtedly there remain several aspects of cancer care that
will require ongoing audit and review, and our own study
highlights the areas that interact and affect the quality of care
for one single chemotherapy-induced complication – febrile
neutropenia. Our study has provided an important and detailed
insight into the incidence and management of chemotherapy-
induced febrile neutropenia in a representative cancer network in
the United Kingdom. Neutropenic complications in cancer
patients are associated with substantial morbidity, mortality and
healthcare costs, warranting research and audit in this area.
We support NCAG’s initiative to encourage chemotherapy
services to undertake regular self-assessment procedures to identify
gaps in their performance and take urgent steps to improve quality
of care. Their recommendations in combination with the NCEPOD
data have aided SWLCN in analysing the results of this study and
putting them in perspective. Areas of potential improvement are
currently being addressed for the hospitals within our cancer
network, based on the results from this study and on the
recommendations set out by NCAG (see Table 6). Improved uptake
of prophylactic G-CSF according to ASCO and ESMO guidelines
(particularly in patients above the age of 65), could reduce the risks
of morbidity and mortality associated with neutropenic sepsis. Time
intervals from arrival to completion of assessment and commence-
ment of treatment for febrile neutropenia need improvement, and to
achieve this, physician and nursing protocols to standardise and
streamline clinical care pathways for the whole network are under
consideration. It is hoped that the recommendation for NICE to
provide a nationwide policy for management of neutropenic sepsis
will lead to a standardised approach within and across networks. A
dedicated specialist committee should review all clinical cases
resulting in death following admission with febrile neutropenia.
Finally, continued audit of current practices should be ongoing, in
order to identify and rectify weaknesses whilst simultaneously
consolidating current quality care.
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